Haleon (NYSE:HLN) Upgraded at Deutsche Bank Aktiengesellschaft

Haleon (NYSE:HLN – Get Free Report) was upgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report released on Friday, Marketbeat reports.

Other research analysts also recently issued reports about the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research report on Friday, September 25th. Wall Street Zen cut shares of Haleon from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Zacks Research cut shares of Haleon from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 22nd. Morgan Stanley restated an “overweight” rating on shares of Haleon in a research note on Thursday, August 6th. Finally, Berenberg Bank reaffirmed a “buy” rating on shares of Haleon in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Haleon has a consensus rating of “Moderate Buy” and a consensus target price of $4.90.

Get Our Latest Stock Analysis on Haleon

Haleon Stock Down 14.5%

Shares of NYSE:HLN opened at $8.55 on Friday. The company has a market capitalization of $37.68 billion, a PE ratio of 21.94, a P/E/G ratio of 2.26 and a beta of 0.14. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. Haleon has a twelve month low of $8.38 and a twelve month high of $11.28. The firm has a 50 day simple moving average of $9.56 and a 200-day simple moving average of $9.78.

Institutional Investors Weigh In On Haleon

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank Julius Baer & Co. Ltd Zurich boosted its holdings in shares of Haleon by 4.9% in the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 4,701,182 shares of the company’s stock valued at $42,409,000 after acquiring an additional 219,567 shares during the period. Profund Advisors LLC increased its holdings in shares of Haleon by 12.1% in the 3rd quarter. Profund Advisors LLC now owns 55,100 shares of the company’s stock valued at $496,000 after acquiring an additional 5,929 shares during the period. Vise Technologies Inc. raised its position in Haleon by 48.0% in the 3rd quarter. Vise Technologies Inc. now owns 79,286 shares of the company’s stock valued at $714,000 after purchasing an additional 25,697 shares during the last quarter. Founders Financial Securities LLC raised its position in Haleon by 2.3% in the 3rd quarter. Founders Financial Securities LLC now owns 281,649 shares of the company’s stock valued at $2,535,000 after purchasing an additional 6,205 shares during the last quarter. Finally, D.A. Davidson & CO. boosted its stake in Haleon by 22.0% during the 3rd quarter. D.A. Davidson & CO. now owns 18,462 shares of the company’s stock worth $166,000 after purchasing an additional 3,330 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Company Profile

(Get Free Report)

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.

Featured Articles

Analyst Recommendations for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.